Cardiovalve
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Yahadut Canada St, Or Yehuda, Tel Aviv...Website
www.cardiovalve.comRevenue
<$5 MillionIndustry
About Cardiovalve
Cardiovalve Org Chart
Is Cardiovalve your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Cardiovalve recently announced quarterly report
Product Launch: Get notified when Cardiovalve launches new products
Check out if Cardiovalve is spiking on competitors!
Funding: Get notified immidiatlly once Cardiovalve has new funding data
Check if Cardiovalve has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cardiovalve had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cardiovalve
Website visits: Recent activity has been detected on your website
Cardiovalve, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Cardiovalve as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Cardiovalve is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cardiovalve is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cardiovalve.
Cardiovalve Tech Stack
A closer look at the technologies used by Cardiovalve
Most Recent Scoops
Cardiovalve News & Media
Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion
Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting. LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK) today announced that Cardiovalve has submitted the CE technical file for its transcatheter tricuspid...Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward EuCourt Sides with Cardiovalve in Edwards patent spat
HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards...Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve
HANGZHOU, China, Jan. 25, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cardiovalve
Cardiovalve specializes in pioneering structural heart innovations, particularly through its flagship Cardiovalve system designed for transfemoral delivery. This novel transcatheter valve replacement system caters to both Mitral and Tricuspid anatomies, offering significant benefits such as minimal protrusion and a robust anchoring mechanism. The C... Read More
